Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Anastomosis Device Market
The global anastomosis device market was valued at USD 4,965.48 million in 2025 and is projected to reach USD 8,976.67 million by 2035, expanding at a CAGR of 6.1% over the forecast period. Growth is driven by increasing adoption of minimally invasive surgical techniques and rising prevalence of chronic diseases requiring surgical intervention. The market remains concentrated among established medical technology and pharmaceutical firms, with innovation in device design and materials supporting procedural efficiency.
Market size
Growth trajectory through 2035
Anastomosis Device Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025
- 2025-Q1: FDA cleared a novel bioabsorbable anastomosis sealant designed for gastrointestinal procedures, enabling faster healing and reduced post-operative complications. The device integrates with robotic surgical platforms, supporting minimally invasive workflows.
-
2025
- 2025-Q2: Johnson & Johnson announced the acquisition of a European automated suturing startup to expand its portfolio in high-precision anastomosis devices. The deal aligns with the company’s strategy to enhance procedural efficiency in cardiovascular and orthopedic surgeries.
-
2025
- 2025-Q3: A clinical study published in JAMA Surgery demonstrated a 22% reduction in anastomotic leaks using a next-generation synthetic adhesive compared to traditional sutures. The findings are expected to drive adoption in high-volume surgical centers.
Emerging opportunities added
- Expansion in emerging markets Increasing healthcare expenditure and surgical training programs in Asia-Pacific and Latin America present significant growth opportunities for anastomosis device manufacturers.
- Integration with digital surgery platforms Development of anastomosis devices compatible with robotic and image-guided systems could enhance procedural precision and expand application scope.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $4.97 Bn
- CAGR
- 6.10%
- Expansion
- 1.8×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High cost of advanced devices
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
2025-Q1: FDA cleared a novel bioabsorbable anastomosis sealant designed for gastrointestinal procedures, enabling faster healing and reduced post-operative complications. The device integrates with robotic surgical platforms, supporting minimally invasive workflows
+2 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 120-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Anastomosis Device Market today ($4.97 Bn base), and how fast will it grow at 6.1% CAGR through 2035?
- Which of Surgical Staplers, Surgical Sutures, Automated Suturing Devices and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Gastrointestinal Surgeries, Cardiovascular Surgeries, Orthopedic Surgeries applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do 3M Health Care, Smith & Nephew, Molnlycke Health Care and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of chronic diseases) and top restraints (led by High cost of advanced devices), with quantified CAGR impact?
- What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of chronic diseases Increasing incidence of conditions such as diabetes and cardiovascular disorders is driving demand for surgical interventions that require anastomosis devices.
- Growth of minimally invasive procedures Adoption of laparoscopic and robotic-assisted surgeries is expanding, creating higher demand for specialized anastomosis tools that support precision and reduced recovery times.
- Technological advancements in device materials Development of bioabsorbable and synthetic sealants with improved biocompatibility and strength is enhancing clinical outcomes and driving market adoption.
Restraints
Holding it back
- High cost of advanced devices Premium-priced anastomosis devices and associated consumables limit adoption in price-sensitive markets and among smaller healthcare facilities.
- Stringent regulatory requirements Protracted approval timelines for new device platforms, particularly in high-growth regions, can delay market entry and increase development costs.
- Competition from alternative closure methods Sutures and staples remain dominant in many procedures, with cost and familiarity acting as barriers to adoption of newer anastomosis technologies.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of chronic diseases | +2.7% | Global | 2025–2035 |
| Growth of minimally invasive procedures | +1.7% | Global | 2025–2035 |
| Technological advancements in device materials | +1.3% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High cost of advanced devices | −1.1% | Global | 2025–2029 |
| Stringent regulatory requirements | −0.7% | Global | 2025–2029 |
| Competition from alternative closure methods | −0.5% | Global | 2025–2029 |
The anastomosis device market is segmented by product type, application, end user, and region. Product categories include surgical staplers, sutures, automated suturing devices, and sealants/adhesives. Applications span gastrointestinal, cardiovascular, orthopedic, ophthalmic, gynecological, and other surgeries. End users include hospitals, ambulatory surgical centers, and clinics.
Revenue share by type · 2025 base year
% OF $4.97 BN ANASTOMOSIS DEVICE MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $4.97 Bn Anastomosis Device Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Surgical Staplers
-
Surgical Sutures
-
Automated Suturing Devices
-
Surgical Sealants
-
Adhesives
By application
-
Gastrointestinal Surgeries
-
Cardiovascular Surgeries
-
Orthopedic Surgeries
-
Ophthalmic Surgeries
-
Gynecological Surgeries
-
Other Surgeries
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $4.97 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~37.2% in 2025. The region accounted for a significant share of the market in 2025, driven by high adoption of advanced surgical technologies and strong reimbursement frameworks
Per-region detail
-
North America
The region accounted for a significant share of the market in 2025, driven by high adoption of advanced surgical technologies and strong reimbursement frameworks
-
Europe
Growth is supported by increasing procedural volumes and regulatory emphasis on patient safety and device innovation
-
Asia-Pacific
Rapid expansion is expected due to rising healthcare investments, growing surgical caseloads, and increasing penetration of minimally invasive techniques
-
Latin America
Market growth is supported by expanding healthcare infrastructure and rising demand for cost-effective anastomosis solutions
-
Middle East & Africa
Growth is driven by improving healthcare access and increasing adoption of modern surgical practices in select urban centers
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The anastomosis device market is moderately concentrated, with leading players leveraging strong distribution networks and continuous innovation to maintain market position.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
3M Health Care
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Smith & Nephew
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Molnlycke Health Care
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Coloplast A/S
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
ConvaTec Group
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Cardinal Health
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Owens & Minor
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Kimberly-Clark Health Care
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Anastomosis Device Market in 2025?
The Anastomosis Device Market is estimated at approximately $4.97 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 6.10% CAGR from 2025 to 2035, reaching $8.98 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 37.2% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Surgical Staplers leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including 3M Health Care, Smith & Nephew, Molnlycke Health Care, Coloplast A/S, ConvaTec Group, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of chronic diseases. Increasing incidence of conditions such as diabetes and cardiovascular disorders is driving demand for surgical interventions that require anastomosis devices.
-
What are the main restraints?
The primary restraint is High cost of advanced devices. Premium-priced anastomosis devices and associated consumables limit adoption in price-sensitive markets and among smaller healthcare facilities.
-
What are the most recent developments?
Recent notable events include: 2025: 2025-Q1: FDA cleared a novel bioabsorbable anastomosis sealant designed for gastrointestinal procedures, enabling faster healing and reduced post-operative complications. The device integrates with robotic surgical platforms, supporting minimally invasive workflows; 2025: 2025-Q2: Johnson & Johnson announced the acquisition of a European automated suturing startup to expand its portfolio in high-precision anastomosis devices. The deal aligns with the company’s strategy to enhance procedural efficiency in cardiovascular and orthopedic surgeries; 2025: 2025-Q3: A clinical study published in JAMA Surgery demonstrated a 22% reduction in anastomotic leaks using a next-generation synthetic adhesive compared to traditional sutures. The findings are expected to drive adoption in high-volume surgical centers. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Anastomosis Device Market is projected to reach $8.98 Bn by 2035, up from $4.97 Bn in 2025 — a 6.10% CAGR equating to roughly 1.8× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.